Marketing-authorisation holder · United States
GlaxoSmithKline LLC
158 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
158 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 158
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTIDIL1.25mg/5ml · Syrup | Triprolidine | United States | Not marketed | |
| ACTIDIL2.5mg · Tablet | Triprolidine | United States | Not marketed | |
| ACTIFED120mg; 5mg · Capsule, extended release | Pseudoephedrine, Triprolidine | United States | Not marketed | |
| ACTIFED W/ CODEINE10MG/5ML; 30MG/5ML; 1.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Syrup | Codeine, Pseudoephedrine, Triprolidine | United States | Not marketed | |
| AEROSPORIN500,000 units base/vial · Injectable | Polymyxin b | United States | Not marketed | 1980 |
| AGENERASE15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Amprenavir | United States | Not marketed | 1999 |
| AGENERASE150mg | 50mg · Capsule | Amprenavir | United States | Not marketed | 1999 |
| AMERGE1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Naratriptan | United States | Not marketed | 1998 |
| AMOXIL125MG/5ML | 125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG/5ML | 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectivenes · For suspension | Amoxicillin | United States | Marketed | 1974 |
| AMOXIL250MG | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 500MG | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Amoxicillin | United States | Marketed | 1974 |
| ANCEF10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons · Injectable | Cefazolin | United States | Not marketed | 1973 |
| ANORO ELLIPTA0.0625mg base/inh; 0.025mg base/inh · Powder | Umeclidinium bromide, Vilanterol trifenatato | United States | Marketed | 2013 |
| ANSPOR125mg/5ml | 250mg/5ml · For suspension | Cephradine | United States | Not marketed | 1974 |
| ANSPOR250mg | 500mg · Capsule | Cephradine | United States | Not marketed | 1974 |
| ANTEPAR500mg base · Tablet | Piperazine | United States | Not marketed | 1957 |
| ANTEPAR500mg base/5ml · Syrup | Piperazine | United States | Not marketed | 1957 |
| ARNUITY ELLIPTA0.05mg/inh | 0.1mg/inh | 0.2mg/inh · Powder | Fluticasone | United States | Marketed | 2014 |
| BACTOCILL10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Oxacilina | United States | Not marketed | 1982 |
| BACTOCILL250mg base | 500mg base · Capsule | Oxacilina | United States | Not marketed | 1973 |
| BACTOCILL250mg base/5ml · For solution | Oxacilina | United States | Not marketed | 1981 |
| BACTROBAN2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Mupirocin | United States | Not marketed | 1995 |
| BACTROBAN2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Cream | Mupirocin | United States | Not marketed | 1997 |
| BACTROBAN2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Mupirocin | United States | Not marketed | 1987 |
| BECLOVENT0.042mg/inh · Aerosol, metered | Beclometasone | United States | Not marketed | 1980 |
| BECONASE0.042mg/inh · Aerosol, metered | Beclometasone | United States | Not marketed | 1981 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 158 | 155 | 3 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.